Inotiv
NOTVNOTV · Stock Price
Historical price data
Overview
Inotiv operates as a full-service CRO and research model vendor, with a mission to 'Analyze, Answer, Advance' for its partners in the life sciences. Founded in 1974, the company has built a 50-year legacy, offering an integrated suite of services spanning discovery, safety assessment, and research model supply. Its strategy is centered on a 'contract to discover partnership' model, aiming to provide deep scientific collaboration rather than transactional services, though it faces significant financial and operational headwinds.
Technology Platform
An integrated service platform combining a full suite of nonclinical CRO capabilities (discovery, DMPK, toxicology, pathology) with one of the industry's broadest portfolios of research models, genetically engineered model services (GEMS), and laboratory animal diet/bedding products.
Pipeline
1| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Spinosad Topical | Scabies | Approved |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Inotiv competes with large, integrated public CROs like Charles River Laboratories and LabCorp's Covance, as well as specialized CROs and research model vendors like The Jackson Laboratory. Its differentiated integrated model is countered by its smaller scale and significant financial instability relative to key peers.